JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Want to see JP:4552 full AI Analyst Report?
4552 Stock Chart & Stats
¥712.00
-¥21.00(-3.43%)
At close: 4:00 PM EST
¥712.00
-¥21.00(-3.43%)
Day’s Range― - ―
52-Week Range¥448.00 - ¥824.00
Previous CloseN/A
Volume326.50K
Average Volume (3M)578.69K
Market Cap
¥61.01B
Enterprise Value¥102.22B
Total Cash (Recent Filing)¥13.18B
Total Debt (Recent Filing)¥40.10B
Price to Earnings (P/E)31.8
Beta0.89
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)-45.01
Shares Outstanding129,686,310
10 Day Avg. Volume668,090
30 Day Avg. Volume578,686
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)1.48
Price to Sales (P/S)1.72
P/FCF Ratio-5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥900.00Price Target Upside26.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.61
Revenue Forecast (FY)¥40.70B
Bulls Say, Bears Say
Bulls Say
Specialty / Rare-disease FocusJCR's focus on biologics and rare-disease therapies creates a durable commercial niche with higher barriers to entry, pricing leverage under reimbursement frameworks, and specialized clinical demand. This positions the company to sustain differentiated revenue streams over multiple years.
Manufacturing & Contract CapabilitiesEstablished manufacturing and contract-production capabilities diversify revenue and improve capacity utilization. Long-term, these assets create sticky customer relationships, recurring service income, and operational leverage that can stabilize cash flow when product sales fluctuate.
Revenue Recovery & Gross ProfitA strong revenue rebound and stable gross margins indicate resilient product demand and pricing power. Sustained top-line recovery paired with consistent gross profit supports long-term margin sustainability, enabling reinvestment in R&D and product lifecycle activities.
Bears Say
Weak Operating Cash FlowRepeated negative operating and free cash flow materially increases funding risk and dependence on external financing. Over the medium term this can constrain R&D, capex, and commercialization plans, and forces prioritization that may slow strategic initiatives or dilute equity if capital raised.
Rising LeverageA meaningful increase in debt reduces financial flexibility and raises interest and refinancing risk. If margins or cash generation falter, higher leverage could pressure liquidity, limit strategic options, and elevate the chance of covenant stress or costly financing needs over the next several quarters.
Profitability VolatilityLarge year-to-year swings in operating results undermine earnings predictability and planning. Volatile profitability complicates investment decisions, heightens perceived execution risk, and makes long-term margin improvement uncertain absent clearer product diversification or sustained cost discipline.
JCR Pharmaceuticals Co., Ltd. News
4552 FAQ
What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥448.00 and its highest was ¥824.00 in the past 12 months.
What is JCR Pharmaceuticals Co., Ltd.’s market cap?
JCR Pharmaceuticals Co., Ltd.’s market cap is ¥61.01B.
When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is Jul 29, 2026 which is in 69 days.
How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?
JCR Pharmaceuticals Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥3.57 earnings per share for the quarter, beating the consensus estimate of -¥6.628 by ¥10.198.
Is JCR Pharmaceuticals Co., Ltd. overvalued?
According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Undervalued.
Does JCR Pharmaceuticals Co., Ltd. pay dividends?
JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 2.71%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here
What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?
JCR Pharmaceuticals Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?
JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.
What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥3.57 in its last earnings report, beating expectations of -¥6.628. Following the earnings report the stock price went up 0.896%.
Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
4552 Stock 12 Month Forecast
Average Price Target
¥900.00
▲(26.40% Upside)
Technical Analysis
Kyowa Kirin Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---